102 Alternatively, quite a few groups are advocating for that incorporation of novel markers, such as a intricate karyotype55 or epigenetic subsets, 27,28 into clinical follow. These novel prognostic and/or predictive versions will must be validated in cohorts of patients dealt with with qualified a